This Drugs for Benign Prostatic hypertrophy market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.28 billion in 2024 to $4.58 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access.
The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development.
The global growth in the male geriatric population is a key driver of the drugs for benign prostatic hypertrophy market since this condition is commonly observed in men aged 50 and above. As an example, in October 2022, the World Health Organization, a US-based specialized health agency, reported that by 2030, an estimated 1 in 6 individuals globally would be 60 years or older, and this figure is projected to increase to 2.1 billion elderly individuals by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia (BPH) affects approximately 50% of men aged between 51 and 60 years, and this percentage rises to as high as 90% among men aged over 80 years.
The growth of the drugs for benign prostatic hypertrophy (BPH) market is expected to be driven by the increasing prevalence of prostate diseases. Prostate diseases encompass a range of medical conditions affecting the prostate gland, a male reproductive organ located just below the bladder. Drugs for BPH play a crucial role in managing and alleviating urinary symptoms related to prostate conditions, offering relief by reducing prostate enlargement and improving urine flow. For instance, in June 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, there were 236,659 new cases of prostate cancer reported in the United States in 2021, with 33,363 men succumbing to the disease in 2022. Therefore, the rising incidence of prostate diseases is driving the growth of the BPH drug market.
Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on developing innovative products, such as Polish drugs, to effectively support patients with urological diseases. Polish drugs are pharmaceutical products developed to diagnose, treat, prevent, or alleviate symptoms of various diseases and conditions, regulated by relevant health authorities to ensure safety, efficacy, and quality. For instance, in June 2023, Adamed Sp. z o.o., a Poland-based pharmaceutical company, launched a combination drug containing solifenacin succinate and tamsulosin hydrochloride. This fixed-dose medication effectively addresses lower urinary tract symptoms (LUTS) associated with BPH by reducing bladder contractions through solifenacin and facilitating urination with tamsulosin. The combination improves patient outcomes when compared to tamsulosin monotherapy.
Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on technological advancements, such as developing new medications that address both enlarged prostate (BPH) and erectile dysfunction (ED), to gain a competitive edge. BPH refers to the non-cancerous enlargement of the prostate gland, while ED is the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical contract manufacturer, launched the Tamsulosin + Tadalafil Capsule, expanding its product offerings in the men's health sector. This innovative product, branded Cromax, combines Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, with Tadalafil, which enhances blood flow to the penis to facilitate erections. This dual-action formulation provides a convenient treatment option for men suffering from both BPH and ED, while also demonstrating significant improvements in the International Prostate Symptom Score (IPSS).
Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International PLC, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.
Benign prostatic hypertrophy drugs are used to treat enlarged prostate glands by relaxing the muscles in the bladder neck and the muscle fibers in the prostate, thereby facilitating easier urination. Benign prostatic hypertrophy is a condition commonly observed in men over the age of 50.
The primary categories of drugs used for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other medications. Alpha-blockers, also known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that functions by blocking adrenergic receptors. These drugs are used in various sectors, including hospital pharmacies, retail pharmacies, and others, and they are distributed through a range of channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.
The drugs for benign prostatic hypertrophy market research report is one of a series of new reports that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the drugs for benign prostatic hypertrophy market in 2024. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.28 billion in 2024 to $4.58 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access.
The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development.
The global growth in the male geriatric population is a key driver of the drugs for benign prostatic hypertrophy market since this condition is commonly observed in men aged 50 and above. As an example, in October 2022, the World Health Organization, a US-based specialized health agency, reported that by 2030, an estimated 1 in 6 individuals globally would be 60 years or older, and this figure is projected to increase to 2.1 billion elderly individuals by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia (BPH) affects approximately 50% of men aged between 51 and 60 years, and this percentage rises to as high as 90% among men aged over 80 years.
The growth of the drugs for benign prostatic hypertrophy (BPH) market is expected to be driven by the increasing prevalence of prostate diseases. Prostate diseases encompass a range of medical conditions affecting the prostate gland, a male reproductive organ located just below the bladder. Drugs for BPH play a crucial role in managing and alleviating urinary symptoms related to prostate conditions, offering relief by reducing prostate enlargement and improving urine flow. For instance, in June 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, there were 236,659 new cases of prostate cancer reported in the United States in 2021, with 33,363 men succumbing to the disease in 2022. Therefore, the rising incidence of prostate diseases is driving the growth of the BPH drug market.
Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on developing innovative products, such as Polish drugs, to effectively support patients with urological diseases. Polish drugs are pharmaceutical products developed to diagnose, treat, prevent, or alleviate symptoms of various diseases and conditions, regulated by relevant health authorities to ensure safety, efficacy, and quality. For instance, in June 2023, Adamed Sp. z o.o., a Poland-based pharmaceutical company, launched a combination drug containing solifenacin succinate and tamsulosin hydrochloride. This fixed-dose medication effectively addresses lower urinary tract symptoms (LUTS) associated with BPH by reducing bladder contractions through solifenacin and facilitating urination with tamsulosin. The combination improves patient outcomes when compared to tamsulosin monotherapy.
Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on technological advancements, such as developing new medications that address both enlarged prostate (BPH) and erectile dysfunction (ED), to gain a competitive edge. BPH refers to the non-cancerous enlargement of the prostate gland, while ED is the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical contract manufacturer, launched the Tamsulosin + Tadalafil Capsule, expanding its product offerings in the men's health sector. This innovative product, branded Cromax, combines Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, with Tadalafil, which enhances blood flow to the penis to facilitate erections. This dual-action formulation provides a convenient treatment option for men suffering from both BPH and ED, while also demonstrating significant improvements in the International Prostate Symptom Score (IPSS).
Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International PLC, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.
Benign prostatic hypertrophy drugs are used to treat enlarged prostate glands by relaxing the muscles in the bladder neck and the muscle fibers in the prostate, thereby facilitating easier urination. Benign prostatic hypertrophy is a condition commonly observed in men over the age of 50.
The primary categories of drugs used for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other medications. Alpha-blockers, also known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that functions by blocking adrenergic receptors. These drugs are used in various sectors, including hospital pharmacies, retail pharmacies, and others, and they are distributed through a range of channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.
The drugs for benign prostatic hypertrophy market research report is one of a series of new reports that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the drugs for benign prostatic hypertrophy market in 2024. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Drugs for Benign Prostatic hypertrophy Market Characteristics3. Drugs for Benign Prostatic hypertrophy Market Trends and Strategies4. Drugs for Benign Prostatic hypertrophy Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Drugs for Benign Prostatic hypertrophy Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Drugs for Benign Prostatic hypertrophy Market34. Recent Developments in the Drugs for Benign Prostatic hypertrophy Market
5. Global Drugs for Benign Prostatic hypertrophy Growth Analysis and Strategic Analysis Framework
6. Drugs for Benign Prostatic hypertrophy Market Segmentation
7. Drugs for Benign Prostatic hypertrophy Market Regional and Country Analysis
8. Asia-Pacific Drugs for Benign Prostatic hypertrophy Market
9. China Drugs for Benign Prostatic hypertrophy Market
10. India Drugs for Benign Prostatic hypertrophy Market
11. Japan Drugs for Benign Prostatic hypertrophy Market
12. Australia Drugs for Benign Prostatic hypertrophy Market
13. Indonesia Drugs for Benign Prostatic hypertrophy Market
14. South Korea Drugs for Benign Prostatic hypertrophy Market
15. Western Europe Drugs for Benign Prostatic hypertrophy Market
16. UK Drugs for Benign Prostatic hypertrophy Market
17. Germany Drugs for Benign Prostatic hypertrophy Market
18. France Drugs for Benign Prostatic hypertrophy Market
19. Italy Drugs for Benign Prostatic hypertrophy Market
20. Spain Drugs for Benign Prostatic hypertrophy Market
21. Eastern Europe Drugs for Benign Prostatic hypertrophy Market
22. Russia Drugs for Benign Prostatic hypertrophy Market
23. North America Drugs for Benign Prostatic hypertrophy Market
24. USA Drugs for Benign Prostatic hypertrophy Market
25. Canada Drugs for Benign Prostatic hypertrophy Market
26. South America Drugs for Benign Prostatic hypertrophy Market
27. Brazil Drugs for Benign Prostatic hypertrophy Market
28. Middle East Drugs for Benign Prostatic hypertrophy Market
29. Africa Drugs for Benign Prostatic hypertrophy Market
30. Drugs for Benign Prostatic hypertrophy Market Competitive Landscape and Company Profiles
31. Drugs for Benign Prostatic hypertrophy Market Other Major and Innovative Companies
35. Drugs for Benign Prostatic hypertrophy Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Drugs for Benign Prostatic hypertrophy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on drugs for benign prostatic hypertrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drugs for benign prostatic hypertrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drugs for benign prostatic hypertrophy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Alpha Blocker; 5-alpha Reductase Inhibitor; Phosphodiesterase-5 Inhibitor; Other Types2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
Subsegments:
1) By Alpha Blocker: Tamsulosin; Alfuzosin; Doxazosin; Terazosin; Silodosin2) By 5-alpha Reductase Inhibitor: Finasteride; Dutasteride
3) By Phosphodiesterase-5 Inhibitor: Tadalafil; Sildenafil
4) By Other Types: Anticholinergics; Herbal Supplements (Saw Palmetto); Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
Key Companies Mentioned: Allergan Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Drugs for Benign Prostatic hypertrophy market report include:- Allergan Inc.
- Astellas Pharma Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Limited
- Sanofi S.A.
- Nymox Pharmaceutical Corporation
- Æterna Zentaris Inc.
- Pfizer Inc.
- IntelGenx Technologies Corp.
- Ipsen S.A.
- Novartis International AG
- Antibe Therapeutics Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Quest PharmaTech Inc.
- Bristol-Myers Squibb Company
- Endo Pharmaceuticals Inc.
- Kaken Pharmaceutical Co. Ltd.
- Impax Laboratories Inc.
- GemVax & KAEL Inc.
- Merck & Co. Inc.
- Kissei Pharmaceutical Co. Ltd.
- Abbott Laboratories
- Allium Medical Solutions Ltd.
- Asahi Kasei Corporation
- Asclepion Laser Technologies GmbH
- Boston Scientific Corporation
- Biolitec AG
- Coloplast A/S
- Eli Lilly and Company
- Endo International plc
- IPG Photonics Corporation
- KARL STORZ SE & Co. KG
- LISA Laser Products AG
- Medifocus Inc.
- Olympus Corporation
- Pharex Health Corporation
- PNN Medical A/S
- Quanta S.p.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 4.58 Billion |
| Forecasted Market Value ( USD | $ 5.58 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 41 |
